The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study
Addenbrooke's Charitable Trust, Cambridge University Hospitals
NIHR Cambridge Biomedical Research Centre
Wellcome - MRC Cambridge Stem Cell Institute, University of Cambridge
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study
Abhinav Mathur, David Dutton, Katherine Sturgess, Andrew Hodson et al.
Citations
8 citations
Journal
The Lancet Oncology
Topics
Lymphoma Diagnosis and Treatment
Field-Weighted Citation Impact (FWCI)
3.40
article
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study
Abhinav Mathur, David Dutton, Katherine Sturgess, Andrew Hodson, George Follows, Kim Linton, Abigail Downing, Dominic Culligan, Kaljit Bhuller, Pam McKay, Kate Cwynarski, Anna Santarsieri, David Hopkins, Graham P. Collins, Andrew McMillan, Hannah Hsu, Raheleh Rahbari, Elizabeth H. Phillips, Rachel Trickey, Emily Mitchell, Nicolás Martínez‐Calle, My H. Pham, Henry Lee-Six, Sunil Iyengar, Alex Sternberg, John F. Rudge, Sarah Behan, E. Joanna Baxter, Stephen Booth, Gwyneth Stafford, Natasha Wetherall, Oliver Lomas, Nicholas Coleman, Kirit M. Ardeshna, Thomas Creasey, Michael R. Stratton, Sateesh Nagumantry, Peter Borchmann, Wendy Osborne, Andrew John Davies, Sven Borchmann, Tobias Menne, Mamatha Karanth, Nikhil Shah, Rashesh Sanghvi, Elisa Laurenti, Michelle Furtado, Xiaoyin Zhang, Pauline Brice, Peter J. Campbell, Janina Jablonski, Benjamin J. Uttenthal, Stephen G. Jones, Neil Phillips, Eve Gallop‐Evans, N. Chavda
article en
8 citations
Abstract
No abstract available for this paper.
Publication Tag
The Lancet OncologyVol. 26(1)
Institutions
NHS Blood and Transplant (GB), Nottingham University Hospitals NHS Trust (GB), University College London Hospitals NHS Foundation Trust (GB), Wellcome/MRC Cambridge Stem Cell Institute (GB), University of Cambridge (GB), Royal Cornwall Hospital (GB), West Suffolk NHS Foundation Trust (GB), Sherwood Forest Hospitals NHS Foundation Trust (GB), Peterborough City Hospital (GB), Norfolk and Norwich University Hospitals NHS Foundation Trust (GB), Beatson West of Scotland Cancer Centre (GB), Royal Stoke University Hospital (GB), Aberdeen Royal Infirmary (GB), University Hospitals Bristol NHS Foundation Trust (GB), Royal Berkshire Hospital (GB), Churchill Hospital (GB), Newcastle upon Tyne Hospitals NHS Foundation Trust (GB), Freeman Hospital (GB), Great Western Hospital (GB), University Hospitals of Leicester NHS Trust (GB), Cambridge University Hospitals NHS Foundation Trust (GB), Wellcome Sanger Institute (GB), University Hospital Southampton NHS Foundation Trust (GB), University of Manchester (GB), University of Oxford (GB), Düsseldorf University Hospital (DE), Assistance Publique – Hôpitaux de Paris (FR), Royal Marsden Hospital (GB), The Christie Hospital (GB), Hôpital Saint-Louis (FR), Great Western Hospitals NHS Foundation Trust (GB), Velindre Cancer Centre (GB), University Hospital Cologne (DE), Ipswich Hospital (GB), University Hospitals Bristol and Weston NHS Foundation Trust (GB), Heinrich Heine University Düsseldorf (DE), University College London (GB)
Funders
Amgen, Pfizer, AstraZeneca, Gilead Sciences, Celgene, CSL Behring, Wellcome Trust, BeiGene, Cancer Research UK, National Institute for Health and Care Research, Servier, Swedish Orphan Biovitrum, Medical Research Council, Addenbrooke's Charitable Trust, Cambridge University Hospitals, NIHR Cambridge Biomedical Research Centre, Wellcome - MRC Cambridge Stem Cell Institute, University of Cambridge